T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high
response rates in patients with B cell malignancies, and chimeric antigen receptor T cell …

We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-
derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that …

Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs)
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …

Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR)
is an investigational treatment capable of inducing complete tumor regression of B-cell …

T cells redirected to specific antigen targets with engineered chimeric antigen receptors
(CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR …

Strategies that enhance the function of T cells are critical for immunotherapy. One negative
regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or …